Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Appointed director

Inmune Bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/08/2019 8-K Quarterly results
09/23/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Session 3: Therapeutics: State of the Field Presentation Title: A Biomarker-Directed Approach to Targeting Inflammation in Alzheimer’ s Patients Time and Date: 5:10 PM – 5:30 PM, Sept. 25 Location: Hyatt Regency Sydney, Australia"
09/18/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
09/09/2019 8-K Quarterly results
09/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference"
08/27/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Investor Fact Sheet"
08/15/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
08/09/2019 8-K Quarterly results
08/07/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer"
08/01/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit La Jolla, CA. – Aug. 1, 2019 – INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., co-founder and CEO, will present at the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit, taking place in Boston from Aug. 5 through Aug. 9. “We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” said Dr. Tesi. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.” Below is a schedule ..."
07/30/2019 8-K Quarterly results
07/09/2019 8-K Other Events
07/03/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Co-Founder and CEO Presents at Maxim Group’s Conference on Alzheimer’s Disease La Jolla, CA – July 3, 2019 – INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that R.J. Tesi, M.D., the company’s co-founder and CEO, presented at the Maxim Group ’s conference on Alzheimer’s disease on June 26 in New York. During his presentation, Dr. Tesi addressed how INmune Bio’s drug candidate XPro1595 targets microglial activation and neuroinflammation to treat Alzheimer’s, which may be a key driver in the disease. During the conference, titled “ Alzheimer's Disease – What's Next? Treating Alzheimer's in a Post-Amyloid World ,” Dr. Tesi discussed INmune Bio’s novel approach to treating Alzheimer..."
06/28/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE La Jolla, CA – June 27, 2019 – INmune Bio, Inc. , an immunotherapy company developing treatments that harness the patient’s innate immune system to fight disease, announced today that the peer-reviewed open access scientific journal PLOS ONE published an article titled, “Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures,” summarizing the different effects between NK cell activation in response to tumor cells and cytokine-mediated activation. Co-authored by Dr. Mark Lowdell, Chief Scientific Officer and co-founder at INmune Bio, the paper defines the response of natural killer cells following their encounters with tumor cells an..."
06/26/2019 8-K Investor presentation
Docs: "Investor Presentation"
06/24/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentation"
06/17/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Feature in NetworkNewsWire Broadcast June 11, 2019"
06/06/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio to present Alzheimer’s Drug Candidate XPro1595 at The TNF Conference on June 4, 2019"
06/04/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
05/29/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th"
05/24/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Sublease between INmune Bio Inc. and CTI-Clinical Trial Services, Inc"
05/17/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment to Securities Purchase Agreement between INmune Bio, Inc. and Raymond J. Tesi",
"Amendment to Securities Purchase Agreement between INmune Bio, Inc. and David J. Moss"
05/16/2019 8-K Quarterly results
Docs: "Purchase Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC",
"Registration Rights Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC",
"INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update GlobeNewswire",
"INmune Bio, Inc."
05/13/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "EX - 99.1"
05/06/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
04/29/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Waiver from Pacific Seaboard Investments Ltd"
04/19/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "INmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit LA JOLLA, Calif., April 17, 2019 -- INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Christopher Barnum, Ph.D., Director of Neuroscience and Translational Medicine, will be presenting a poster at the Neuroimmunology Drug Development Summit in Boston on April 17. The poster will address the Phase 1b trial on the company’s drug candidate XPro1595 for patients with mild to moderate Alzheimer’s disease. ”Because of our focus on neuroinflammation as a cause of neurologic disease, we have designed a Phase 1 trial that measures traditional and novel biomarkers of inflammation as a first step in our Alzheimer’s d..."
04/12/2019 8-K Quarterly results
04/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "NASDAQ Closing Bell Release"
03/13/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Website Release"
02/13/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy